Company intelligence / Profile preview
StromaCare
Lyon, Auvergne-Rhône-Alpes, Francestroma.care ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
StromaCare is advancing its lead product, a monoclonal antibody therapy targeting the tumor stroma, toward First-in-Human clinical trials for multiple solid cancers. The company focuses on modulating stromal components to inhibit tumor growth, immune escape, and metastasis while enhancing drug delivery and surgical outcomes. No published clinical results yet; programs are in preclinical or early translational stages.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyBiologic (inferred from monoclonal antibody development)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships have been publicly disclosed.
Beyond the preview
Go deeper on StromaCare.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StromaCare.